Abstract
Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease represent a huge unmet medical need. The prevalence of both diseases is increasing, but the efficacy of treatment is still very limited due to various factors including the blood brain barrier (BBB). Drug delivery to the brain remains the major challenge for the treatment of all neurodegenerative diseases because of the numerous protective barriers surrounding the central nervous system. New therapeutic drugs that cross the BBB are critically needed for treatment of many brain diseases. One of the significant factors on neurotherapeutics is the constraint of the blood brain barrier and the drug release kinetics that cause peripheral serious side effects. Contrary to common belief, neurodegenerative and neurological diseases may be multisystemic in nature, and this presents numerous difficulties for their potential treatment. Overall, the aim of this paper is to summarize the last findings and news related to liposome technology in the treatment of neurodegenerative diseases and demonstrate the potential of this technology for the development of novel therapeutics and the possible applications of liposomes in the two most widespread neurodegenerative diseases, Alzheimer's disease and Parkinson's disease.
Highlights
Each year, over 10 million people globally suffer from neurodegenerative diseases
The central nervous system (CNS) barriers are composed by blood brain barrier (BBB) and blood-cerebrospinal fluid barrier (B-CSFB)
A novel liposome delivery system was developed for direct transport into olfactory epithelium cells with polyethylene glycol (PEG)ylated immunoliposomes directed against human gliofibrillary acidic protein (GFAP)
Summary
Over 10 million people globally suffer from neurodegenerative diseases. This figure is expected to grow by 20% over the decade as the aging population increases and lives longer. 24 million people worldwide suffer from dementia, 60% of cases being due to Alzheimer’s disease, which occurs in 1% of individuals aged 50 to 70 and dramatically increases to 50% for those over 70 years [4]. Gene therapy has evolved as a new treatment for brain diseases, especially for neurodegenerative diseases, where genetically engineered cells can be used to deliver specific growth factors to target cells. One promising technology is the development of new biomaterial components with the capacity of enveloping genetically engineered cells producing and distributing the drug therapy, and, at the same time, to be isolated from immune system This technology includes, among others, the liposomes representing a potential delivery system for specific proteins and growth factors to brain damage, where different producer cells may be isolated from the microenvironmental factors [20]. This paper provides an overview of progress in liposome technology, summarizing the last patents and news related to liposomes, demonstrating the potential of this technology for the development of novel neurotherapeutics and its applications in Alzheimer’s disease and Parkinson’s disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
